ISDA

Deposition Date 2021-09-09

Release Date 2021-09-29

Last Version Date 2024-06-19

Entry Detail

PDB ID:

7POR

Keywords:

SIGNALING PROTEIN

Title:

PI3 kinase delta in complex with N-[2-(2-fluoro-4-{[4-(propan-2-yl)piperazin-1-yl]methyl}phenyl)pyridin-4-yl]-2-methoxy-5-(morpholin-4-yl)pyridine-3-sulfonamide

Biological Source:

Source Organism:

Mus musculus (Taxon ID: 10090)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.26 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.19

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Gene (Uniprot):Pik3cd
Chain IDs:A
Chain Length:940
Number of Molecules:1
Biological Source:Mus musculus

UniProt ID:O35904 Pfam ID:PF00794, PF00792, PF00613, PF00454 EC:2.7.1.153

Ligand Molecules

7XH

Primary Citation

Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3K delta with a Novel Binding Mode.

Down, K, Amour, A, Anderson, N.A, Barton, N, Campos, S, Cannons, E.P, Clissold, C, Convery, M.A, Coward, J.J, Doyle, K, Duempelfeld, B, Edwards, C.D, Goldsmith, M.D, Krause, J, Mallett, D.N, McGonagle, G.A, Patel, V.K, Rowedder, J, Rowland, P, Sharpe, A, Sriskantharajah, S, Thomas, D.A, Thomson, D.W, Uddin, S, Hamblin, J.N, Hessel, E.M.Show

J.Med.Chem. 64 13780 13792 (2021)

PMID: 34510892 DOI: 10.1021/acs.jmedchem.1c01102

Abstact

Optimization of a previously reported lead series of PI3Kδ inhibitors with a novel binding mode led to the identification of a clinical candidate compound 31 (GSK251). Removal of an embedded Ames-positive heteroaromatic amine by reversing a sulfonamide followed by locating an interaction with Trp760 led to a highly selective compound 9. Further optimization to avoid glutathione trapping, to enhance potency and selectivity, and to optimize an oral pharmacokinetic profile led to the discovery of compound 31 (GSK215) that had a low predicted daily dose (45 mg, b.i.d) and a rat toxicity profile suitable for further development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures